Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed and dated a consent form agreeing to take part in the study.
- People who are willing to follow all study procedures and are available for the full duration of the trial.
- People who have at least one risk factor for cardiovascular (heart and blood vessel) disease, such as: being aged 50 or older, high blood pressure, high cholesterol, diabetes, being a current or former smoker, having a close family member (parent, sibling, or child) with heart disease, having a body mass index (BMI) over 25, or currently taking blood pressure medication, a cholesterol-lowering drug (statin), and/or aspirin.
- People who have been diagnosed with localised (not spread) prostate cancer that is considered low or intermediate risk, meaning: a PSA blood test result of 20.0 ng/ml or below, an early clinical stage of the cancer (T1c or cT2), and a Gleason score of 3+3, 3+4, or 4+3 (confirm with trial site if unsure about these scores).
- People who are currently on Active Surveillance (a monitoring approach rather than immediate treatment) and have a planned follow-up biopsy scheduled.
- People who have not previously received any treatment for prostate cancer, including radiation therapy, chemotherapy, or hormone therapy.
- People who are able to swallow tablets and are willing to take a once-daily oral medication (either Vytorin or ezetimibe) as directed.
- People who agree to avoid eating grapefruit or drinking large amounts of grapefruit juice (one quart or more per day) throughout the study.
Who may not be able to join:
- People who are currently taking certain medications that are known to interact dangerously with statins, including some antifungal, antibiotic, HIV, or antidepressant medications (confirm with trial site for the full list).
- People who are currently taking medications known to interact with ezetimibe, such as gemfibrozil, cyclosporine, or danazol.
- People who have had an allergic reaction or a serious adverse reaction to either of the study medications in the past.
- People who have a history of moderate or severe muscle pain (myalgia) caused by statin use.
- People who have acute (sudden, severe) liver failure or advanced liver scarring (decompensated cirrhosis).
- People who are already taking the highest available dose of Vytorin (the 10/80 dose).
- People who are already taking other medications that are known to interact with Vytorin or ezetimibe in a way that would prevent the study from adjusting the cholesterol-lowering medication as planned.
- People who are already taking a PCSK9 inhibitor (a type of cholesterol-lowering injection medication).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hyung Kim, MD, Cedars-Sinai Medical Center
Phone: 310-423-1542
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pre/Post-change in percent prostate infiltrating CD8+ T lymphocytes.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.